ABSTRACT:
Parkinson disease is a degenerative disease affecting the neurological system and the body components controlled by nerves. Prototype of dopamine is levodopa. Instead of dopamine, levodopa is the medication that doctors usually prescribe to treat Parkinson disease. Extended levodopa therapy patients have to deal with few unintended side effects. Combining levodopa with carbidopa was used to treat Parkinson's disease and symptoms similar to Parkinson's disease in order to reduce these negative effects. In this work, nanoliposomes were developed and then applied to the formulation of nanocochleates to improve stability and bioavailability. Liposomes were prepared by the two most often used preparative techniques: ethanol injection and reverse phase evaporation. A basic technique that could be used for pharmacokinetics research as well as to identify and measure real medicines in formulation was also developed and validated during the project. The final formulations were assessed using morphological observation, zeta potential and particle size analysis, percentage drug loading and % entrapment efficiency. These characteristics were used to further manufacture nanocochleates using LDNL3 formulation. Particle size and zeta potential analysis, drug loading percentage, % entrapment efficiency, XRD, in vitro release research and HRTEM were all used to assess the resultant nanocochleates. The efficiency of our developed formulation was confirmed by the HRTEM examination, which also guaranteed its shape. As a result, we came to the conclusion that the created formulation worked better at modest doses.